Cognitive · Amino Acid

DL-Phenylalanine (DLPA)

📄 5 PubMed citations

A racemic amino acid with two jobs: the L-isomer feeds the dopamine precursor pathway, and the D-isomer is a putative enkephalinase inhibitor tied to endogenous endorphins.

🔬 DLPA is an essential-amino-acid supplement, not a drug. We separate the real precursor/enkephalinase mechanisms from the thin, dated clinical data — and flag the PKU contraindication.
0
Isomers in DL-phenylalanine (L- and D-)
0
Downstream targets: dopamine, norepinephrine, PEA
0
FDA-approved DLPA drug indications

How It Works

🧬
L-isomer → dopamine substrate

L-phenylalanine is hydroxylated to L-tyrosine, the direct precursor for dopamine and norepinephrine. It refills the same substrate pool that L-tyrosine supplementation targets. L-Tyrosine guide →

🔒
D-isomer → enkephalinase inhibition

D-phenylalanine is a putative inhibitor of enkephalinase, the enzyme that degrades enkephalins, studied in a primate acute-pain model (PMID 3515291). This is the mechanistic basis for a raised endogenous-endorphin "baseline."

⚖️
DL = both at once

The DL racemic mix supplies both isomers, which is why DLPA is pitched as a dopamine-precursor and endorphin-preserving amino acid rather than doing just one or the other.

🙂
Phenylalanine & mood (dated data)

Small, mostly 1980s studies explored phenylalanine supplements in depression via the phenylethylamine pathway (PMID 3944066, 6490415). The signal is real but the trials are small, old and easily overstated.

What the Data Shows

D-Phe enkephalinase inhibition
Primate + preclinical models · editorial evidence strength
Preclinical
D-Phe chronic-pain analgesia
Small clinical studies, 1980s · editorial evidence strength
Small trials
Phenylalanine & mood/depression
Small/dated supplementation trials · editorial evidence strength
Small/dated
DLPA for focus specifically
No direct human focus/attention trials · editorial evidence strength
None direct

Key Takeaways

✅ What We Know
  • L-phenylalanine converts to L-tyrosine, so it can feed the same dopamine/norepinephrine precursor pathway as tyrosine.
  • D-phenylalanine acts as a putative enkephalinase inhibitor in preclinical and primate pain models — a genuine mechanism for preserving endogenous endorphins.
  • Small D-phenylalanine studies reported analgesic effects in chronic pain patients (PMID 3524509).
  • DLPA is an over-the-counter essential-amino-acid supplement, widely available and inexpensive.
  • People with phenylketonuria (PKU) must avoid phenylalanine entirely — this is a hard contraindication, not a caution.
⚠️ What We Don't Know
  • There are no direct human trials showing DLPA improves focus or attention — the "focus" use is extrapolated from precursor logic, not measured.
  • The mood/antidepressant data is small, mostly from the 1980s, and should not be read as proof of efficacy.
  • Optimal dose, timing and L:D ratio for any cognitive goal are not established; dosing here is educational context only.
  • Endorphin "baseline" effects in healthy users are inferred from pain-model pharmacology, not demonstrated in cognition studies.
  • Long-term safety of chronic high-dose supplementation is not well characterized.

Frequently Asked Questions

What is DLPA?

DLPA is DL-phenylalanine, a 50/50 racemic mixture of the L- and D- forms of the essential amino acid phenylalanine. The L-form feeds the dopamine/norepinephrine precursor pathway (via tyrosine); the D-form is a putative enkephalinase inhibitor linked to endogenous endorphins. It is sold as a dietary supplement, not a drug.

DLPA vs L-tyrosine — which is better for dopamine?

L-tyrosine is one step closer to dopamine, so for pure precursor loading it is the more direct choice. DLPA sits further upstream but adds the D-isomer endorphin mechanism that tyrosine lacks. If your only goal is dopamine substrate, tyrosine is simpler; DLPA is chosen when the endorphin angle matters.

Does DLPA actually raise endorphins?

The D-isomer inhibits enkephalinase, the enzyme that breaks down enkephalins, in preclinical and primate pain models. That is a plausible route to higher endogenous endorphin tone, but it has been demonstrated in pain pharmacology rather than in cognition or mood trials in healthy people, so treat it as mechanistic rather than proven.

Is DLPA safe?

For most people short-term supplemental use is generally well tolerated, but there is one absolute contraindication: anyone with phenylketonuria (PKU) must avoid all phenylalanine. It may also interact with MAOI antidepressants and is not established as safe in pregnancy. Consult a healthcare provider before use.

Can you take DLPA with the dopamine focus stack?

DLPA is one of the components in the dopamine focus stack, where it plays the dual substrate-plus-endorphin role. See the full stack breakdown for how it sits alongside bromantane, NALT, Vilon and circadian light — and note that the combined stack itself has no trial evidence.

Peer-Reviewed References

Source 1
D-phenylalanine: a putative enkephalinase inhibitor studied in a primate acute pain model.
Pain · 1986
PMID: 3515291
Source 2
Analgesic effectiveness of D-phenylalanine in chronic pain patients.
Arch Phys Med Rehabil · 1986
PMID: 3524509
Source 3
Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements.
J Clin Psychiatry · 1986
PMID: 3944066
Source 4
Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders.
J Am Osteopath Assoc · 1984
PMID: 6490415
Source 5
N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous infusion in humans.
Metabolism · 1989
PMID: 2507878
⚠️ Disclaimer

Educational purposes only. Not medical advice.

DLPA is a dietary supplement, not a treatment for any condition. People with phenylketonuria (PKU) must avoid phenylalanine entirely. May interact with MAOIs. Consult a qualified healthcare provider before use.